Loading clinical trials...
Loading clinical trials...
A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)
Conditions
Interventions
Siplizumab
Locations
1
United States
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
New York, New York, United States
Start Date
September 11, 2024
Primary Completion Date
December 31, 2027
Completion Date
March 31, 2028
Last Updated
November 24, 2025
NCT07315204
NCT04902807
NCT03146884
NCT05750498
NCT05810480
NCT05740358
Lead Sponsor
Elizabeth C. Verna
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions